Skip to content

A single-center prospective cohort study of megestrol combined with oral nutritional supplements in the treatment of malnourished lung cancer

A single-center prospective cohort study of megestrol combined with oral nutritional supplements in the treatment of malnourished lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049007
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Group 1:Megestrol Acetate
Group 2:Megestrol Acetate Combined with Oral Nutrition Supplement

Sponsors

Shaanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed lung cancer patients (18 to 80 years old), nutritional risk score (NRS) >= 3, patient subjective global assessment (PG-SGA) score >= grade B, Eastern Cooperative Oncology Group (ECOG) score = 6 months; 2. Patients can receive anti-tumor chemotherapy, targeted therapy or palliative drug therapy or best supportive care at the same time. Opioids are used to treat cancer pain. The subjects voluntarily participated in this study and signed the informed consent form, and the compliance was good.

Exclusion criteria

Exclusion criteria: Women of child-bearing age and patients with mechanical obstruction to feeding, drug-induced changes in body weight (corticosteroids for prevention of chemotherapy-induced emesis were allowed), thromboembolism, diabetes mellitus, cardiovascular diseases, such as congestive heart failure (New York Heart Association, NYHA >= III), uncontrolled hypertension (systolic pressure > 140 mmHg and diastolic pressure > 90 mmHg), previous myocardial infarction, unstable angina, uncontrolled arrhythmia, previous cerebrovascular accidents, in?ammatory bowel diseases, or gastrointestinal ulcers were excluded.

Design outcomes

Primary

MeasureTime frame
Body mass index;ECOG score;

Secondary

MeasureTime frame
Appetite;Mid-upper arm circumference;Serum pre-albumin;Serum albumin;

Countries

China

Contacts

Public ContactDuan Baojun

Shaanxi Provincial People's Hospital

duanbaojun.cn@163.com+86 18681839195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026